89bio
CA - San FranciscoBiotechnology
Focus: 89bio is a San Francisco-based public biotech company focused on liver disease treatments, particularly metabolic dysfunction-associated steatohepatitis (MASH/NASH). The company operates as a clinical-stage player with a concentrated pipeline in hepatic indications.
Profile data last refreshed 22h ago · AI intelligence enriched 2w ago
Funding Stage
PUBLIC
Open Jobs
0
About 89bio
AI assessmentNot HiringNo open roles listed right now. Follow 89bio to get notified when they start hiring — the background below is worth knowing for when they do.
Generated by Claude from 89bio's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Data completeness
2/9 — Limited
Company HealthSolid
Pipeline
Mid-stage
1 Phase 3+
LOE Risk
Protected
No near-term cliffs
Hiring
0 open
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Pipeline & Clinical Trials
BIO89-100
NASH - Nonalcoholic SteatohepatitisClinical Trials (1)
NCT05022693PK Study of Liquid Formulation of BIO89-100 in Subjects With NASH With Compensation Cirrhosis
Phase 1Help build intelligence for 89bio
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.